Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Head and Neck Cancer

  Free Subscription


Articles published in Radiother Oncol

Retrieve available abstracts of 332 articles:
HTML format



Single Articles


    July 2021
  1. ROBIJNS J, Lodewijckx J, Claes S, Van Bever L, et al
    Response to the Comment on "Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)" by Baiocchi et al.
    Radiother Oncol. 2021 Jul 15. pii: S0167-8140(21)06639.
    PubMed    


  2. MUNARETTO TIMM BAIOCCHI J, Fischer-Sgrott F, Baiocchi Neto G
    Comment on "Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)".
    Radiother Oncol. 2021 Jul 15. pii: S0167-8140(21)06642.
    PubMed    


  3. JO YY, Yu J, Song KJ, Jang JY, et al
    Definitive chemoradiotherapy versus esophagectomy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma: a retrospective study.
    Radiother Oncol. 2021 Jul 12. pii: S0167-8140(21)06643.
    PubMed     Abstract available


  4. BOEKHOFF MR, Defize IL, Borggreve AS, van Hillegersberg R, et al
    An in-silico assessment of the dosimetric benefits of MR-guided radiotherapy for esophageal cancer patients.
    Radiother Oncol. 2021 Jul 5. pii: S0167-8140(21)06626.
    PubMed     Abstract available


  5. VAN DER LAAN HP, van der Schaaf A, Van den Bosch L, Korevaar EW, et al
    Quality of life and toxicity guided treatment plan optimisation for head and neck cancer.
    Radiother Oncol. 2021 Jul 5. pii: S0167-8140(21)06623.
    PubMed     Abstract available


    June 2021
  6. SUN XS, Xie SY, Luo DH, Liu LT, et al
    Impact of smoking on survival in nasopharyngeal carcinoma: A cohort study with 23,325 patients diagnosed from 1990 to 2016.
    Radiother Oncol. 2021 Jun 25. pii: S0167-8140(21)06612.
    PubMed     Abstract available


  7. DONNELLY O, Goranova R, Nugent M
    Letter to the editor regarding the article "Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial)" by Robijns et al. Radiat Oncol. 2021.
    Radiother Oncol. 2021 Jun 15. pii: S0167-8140(21)06579.
    PubMed    


  8. ROBIJNS J, Lodewijckx J, Claes S, Van Bever L, et al
    Response to the Letter to the editor by Donnelly et al. regarding the article "Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial)".
    Radiother Oncol. 2021 Jun 10. pii: S0167-8140(21)06581.
    PubMed    


  9. JIN YN, Yao JJ, You YF, Cao HJ, et al
    Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study.
    Radiother Oncol. 2021 Jun 8. pii: S0167-8140(21)06575.
    PubMed     Abstract available


  10. DE BREE R, Swartz JE, Bril S, Chargi N, et al
    Skeletal muscle mass measurements using head and neck CT imaging in head and neck cancer patients.
    Radiother Oncol. 2021 Jun 6. pii: S0167-8140(21)06573.
    PubMed    


  11. LALONDE A, Bobic M, Winey B, Verburg J, et al
    Anatomic changes in head and neck intensity-modulated proton therapy: Comparison between robust optimization and online adaptation.
    Radiother Oncol. 2021;159:39-47.
    PubMed     Abstract available


    May 2021
  12. JIANG C, Gong B, Gao H, Zhang T, et al
    Correlation analysis of neck node levels in 960 cases of Nasopharyngeal carcinoma (NPC).
    Radiother Oncol. 2021 May 24. pii: S0167-8140(21)06258.
    PubMed     Abstract available


  13. BOEKHOFF MR, Defize IL, Borggreve AS, van Hillegersberg R, et al
    CTV-to-PTV margin assessment for esophageal cancer radiotherapy based on an accumulated dose analysis.
    Radiother Oncol. 2021 May 13. pii: S0167-8140(21)06241.
    PubMed     Abstract available


  14. WANG XY, Zhu SY, Wu WJ, Li HJ, et al
    Extent of Paranasal Sinus Involvement and its Prognostic Value in Nasopharyngeal Carcinoma: Proposed Modification in the Current UICC/AJCC staging system.
    Radiother Oncol. 2021 May 10. pii: S0167-8140(21)06224.
    PubMed     Abstract available


  15. SUN Z, Hu S, Xue Q, Jin L, et al
    Can 3D pseudo-continuous arterial spin labeling perfusion imaging be applied to predict early response to chemoradiotherapy in patients with advanced nasopharyngeal carcinoma?
    Radiother Oncol. 2021 May 2. pii: S0167-8140(21)06214.
    PubMed     Abstract available


  16. CIECIOR W, Ebert N, Borgeaud N, Thames HD, et al
    Sample-size calculation for preclinical dose-response experiments using heterogeneous tumour models.
    Radiother Oncol. 2021;158:262-267.
    PubMed     Abstract available


  17. LAI Y, Zeng X, Zhou K, Zhou X, et al
    End to end intussusception anastomosis decreases the risk of anastomotic leakage after neoadjvant chemoradiation and McKeown oesophagectomy.
    Radiother Oncol. 2021;158:285-292.
    PubMed     Abstract available


  18. HAGUE C, McPartlin A, Lee LW, Hughes C, et al
    An evaluation of MR based deep learning auto-contouring for planning head and neck radiotherapy.
    Radiother Oncol. 2021;158:112-117.
    PubMed     Abstract available


  19. LEE J, Liu SH, Chen JC, Leu YS, et al
    Progressive muscle loss is an independent predictor for survival in locally advanced oral cavity cancer: A longitudinal study.
    Radiother Oncol. 2021;158:83-89.
    PubMed     Abstract available


  20. ZHAO L, Chen S, Chen S, Pang Y, et al
    (68)Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer.
    Radiother Oncol. 2021;158:55-61.
    PubMed     Abstract available


    April 2021
  21. TAMBAS M, der Laan HPV, Rutgers W, van den Hoek JGM, et al
    Development of advanced preselection tools to reduce redundant plan comparisons in model-based selection of head and neck cancer patients for proton therapy.
    Radiother Oncol. 2021 Apr 20. pii: S0167-8140(21)06194.
    PubMed     Abstract available


  22. VAN DER LAAN HP, Van den Bosch L, Schuit E, Steenbakkers RJHM, et al
    aImpact of radiation-induced toxicities on quality of life of patients treated for head and neck cancer.
    Radiother Oncol. 2021 Apr 20. pii: S0167-8140(21)06193.
    PubMed     Abstract available


  23. ELICIN O, Koller Brolese E, Bojaxhiu B, Sermaxhaj B, et al
    The prognostic impact of daytime and seasonality of radiotherapy on head and neck cancer.
    Radiother Oncol. 2021 Apr 10. pii: S0167-8140(21)06185.
    PubMed     Abstract available


  24. ESTEBAN B, Pierre P, Camille S, Pascal P, et al
    Influence of postoperative radiotherapy target volumes in unilateral head and neck carcinoma of unknown primary: a multicentric study using propensity score.
    Radiother Oncol. 2021 Apr 9. pii: S0167-8140(21)06183.
    PubMed     Abstract available


  25. LU ZJ, Liu LT, Sun XS, Guo SS, et al
    Establishment and validation of a prognostic nomogram to predict early metastasis in nasopharyngeal carcinoma patients within six months after radiotherapy and to guide intensive treatment.
    Radiother Oncol. 2021 Apr 8. pii: S0167-8140(21)06175.
    PubMed     Abstract available


  26. YAN JJ, Guo SS, Lin DF, Liu LT, et al
    Development and validation of a normal tissue complication probability model for acquired nasal cavity stenosis and atresia after radical radiotherapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2021 Apr 8. pii: S0167-8140(21)06180.
    PubMed     Abstract available


  27. QIU Y, Guo Z, Lin X, Li J, et al
    Standard radiotherapy for patients with nasopharyngeal carcinoma results in progressive tract-specific brain white matter alterations: A one-year follow-up via diffusion tensor imaging.
    Radiother Oncol. 2021 Apr 8. pii: S0167-8140(21)06179.
    PubMed     Abstract available


  28. ZHANG Y, Feng W, Gao LT, Cai XW, et al
    Long-term follow-up of a phase I/II trial of radiation dose escalation by simultaneous integrated boost for locally advanced esophageal squamous cell carcinoma.
    Radiother Oncol. 2021 Apr 1. pii: S0167-8140(21)06171.
    PubMed     Abstract available


  29. WONG ET, Huang SH, O'Sullivan B, Persaud V, et al
    Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy.
    Radiother Oncol. 2021;157:255-262.
    PubMed     Abstract available


  30. JENSEN GL, Axelrud G, Fink D, Hammonds K, et al
    Improved local control in p16 negative oropharyngeal cancers with hypermethylated MGMT.
    Radiother Oncol. 2021;157:234-240.
    PubMed     Abstract available


  31. BAUWENS L, Baltres A, Fiani DJ, Zrounba P, et al
    Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
    Radiother Oncol. 2021;157:122-129.
    PubMed     Abstract available


  32. GUNN L, Gilbert J, Nenclares P, Soliman H, et al
    Taste dysfunction following radiotherapy to the head and neck: A systematic review.
    Radiother Oncol. 2021;157:130-140.
    PubMed     Abstract available


  33. MEN K, Chen X, Yang B, Zhu J, et al
    Automatic segmentation of three clinical target volumes in radiotherapy using lifelong learning.
    Radiother Oncol. 2021;157:1-7.
    PubMed     Abstract available


  34. STIEB S, Mohamed ASR, He R, Zhu LL, et al
    Development and validation of a contouring guideline for the taste bud bearing tongue mucosa.
    Radiother Oncol. 2021;157:63-69.
    PubMed     Abstract available


    March 2021
  35. LI G, Jiang Y, Li G, Qiao Q, et al
    Comprehensive analysis of radiosensitivity in head and neck squamous cell carcinoma.
    Radiother Oncol. 2021 Mar 25. pii: S0167-8140(21)06143.
    PubMed     Abstract available


  36. LOSER A, Abel J, Magdalena Kutz L, Krause L, et al
    Head and neck cancer patients under (chemo-)radiotherapy undergoing nutritional intervention: results from the prospective randomized headnut-trial.
    Radiother Oncol. 2021 Mar 22. pii: S0167-8140(21)06145.
    PubMed     Abstract available


  37. RUHLE A, Grosu AL, Wiedenmann N, Stoian R, et al
    Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial.
    Radiother Oncol. 2021 Mar 19. pii: S0167-8140(21)06140.
    PubMed     Abstract available


  38. GROSSBERG AJ, Rock CD, Edwards J, Mohamed ASR, et al
    Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy.
    Radiother Oncol. 2021 Mar 15. pii: S0167-8140(21)06131.
    PubMed     Abstract available


  39. ROBIJNS J, Lodewijckx J, Claes S, Van Bever L, et al
    Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial).
    Radiother Oncol. 2021 Mar 9. pii: S0167-8140(21)06117.
    PubMed     Abstract available


  40. CHEN B, Deng M, Yang C, Dragomir MP, et al
    High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: A retrospective analysis.
    Radiother Oncol. 2021 Mar 2. pii: S0167-8140(21)06094.
    PubMed     Abstract available


  41. BROLESE EK, Cihoric N, Bojaxhiu B, Sermaxhaj B, et al
    The impact of delivery daytime and seasonality of radiotherapy for head and neck cancer on toxicity burden.
    Radiother Oncol. 2021 Mar 2. pii: S0167-8140(21)06113.
    PubMed     Abstract available


  42. PATEL S, Patel N, Sassoon I, Patel V, et al
    The use of pentoxifylline, tocopherol and clodronate in the management of osteoradionecrosis of the jaws.
    Radiother Oncol. 2021;156:209-216.
    PubMed     Abstract available


  43. AKBABA S, Ruhle A, Rothhaar S, Zamboglou C, et al
    Treatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy - Results from a large multicenter analysis.
    Radiother Oncol. 2021;156:266-274.
    PubMed     Abstract available


  44. THOMAS M, Mortensen HR, Hoffmann L, Moller DS, et al
    Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer.
    Radiother Oncol. 2021;156:102-112.
    PubMed     Abstract available


  45. HOSNI A, Huang SH, Xu W, Su J, et al
    Healthcare resource utilization following unilateral versus bilateral radiation therapy for oropharyngeal carcinoma.
    Radiother Oncol. 2021;156:95-101.
    PubMed     Abstract available


    February 2021
  46. HUANG TW, Shao CH, Chiang CC
    Response to the letter to the editor "Exercise therapy for cancer treatment-induced trismus in patients with head and neck cancer: A systematic review and meta-analysis of randomized controlled trials regards to Chiu et al."
    Radiother Oncol. 2021 Feb 26. pii: S0167-8140(21)06086.
    PubMed    


  47. CHIU YH, Wang TG
    Letter to the editor regarding Shao et al., Exercise therapy for cancer treatment-induced trismus in patients with head and neck cancer: A systematic review and meta-analysis of randomized controlled trials.
    Radiother Oncol. 2021 Feb 26. pii: S0167-8140(21)06088.
    PubMed    


  48. FAN WJ, Teng F, Liu G, Zhao DW, et al
    Diffusion weighted imaging in submandibular gland sparing helical tomotherapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2021 Feb 12. pii: S0167-8140(21)06050.
    PubMed     Abstract available


  49. NIE D, Wang X, Sun M, Feng Z, et al
    The primary site of head and neck squamous cell carcinoma predicts survival benefits of EGFR inhibitors: a systematic review and meta-analysis.
    Radiother Oncol. 2021 Feb 12. pii: S0167-8140(21)06047.
    PubMed     Abstract available


  50. YANG ES, Deutsch E, Mehmet A, Fayette J, et al
    A phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.
    Radiother Oncol. 2021 Feb 9. pii: S0167-8140(21)06040.
    PubMed     Abstract available


  51. VAN AKEN ESM, Paul van der Laan H, Bijl HP, Van den Bosch L, et al
    Risk of ischaemic cerebrovascular events in head and neck cancer patients is associated with carotid artery radiation dose.
    Radiother Oncol. 2021 Feb 2. pii: S0167-8140(21)06023.
    PubMed     Abstract available


  52. VAN DEN BOSCH L, van der Schaaf A, Paul van der Laan H, Hoebers FJP, et al
    Comprehensive toxicity risk profiling in radiation therapy for head and neck cancer: a new concept for individually optimised treatment.
    Radiother Oncol. 2021 Feb 2. pii: S0167-8140(21)06021.
    PubMed     Abstract available


  53. DIETRICH A, Andreeff M, Koi L, Bergmann R, et al
    Radiotherapy enhances uptake and efficacy of (90)Y-cetuximab: A preclinical trial.
    Radiother Oncol. 2021;155:285-292.
    PubMed     Abstract available


  54. MICHAELIDOU A, Adjogatse D, Suh Y, Pike L, et al
    18F-FDG-PET in guided dose-painting with intensity modulated radiotherapy in oropharyngeal tumours: A phase I study (FiGaRO).
    Radiother Oncol. 2021;155:261-268.
    PubMed     Abstract available


  55. ROSEN BS, Wilkie JR, Sun Y, Ibrahim M, et al
    CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Radiother Oncol. 2021;155:174-181.
    PubMed     Abstract available


    January 2021
  56. MAO Y, Wang S, Lydiatt W, Shah JP, et al
    Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems.
    Radiother Oncol. 2021 Jan 28. pii: S0167-8140(21)00015.
    PubMed     Abstract available


  57. LACAS B, Carmel A, Landais C, Wong SJ, et al
    Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group.
    Radiother Oncol. 2021 Jan 27. pii: S0167-8140(21)00013.
    PubMed     Abstract available


  58. WEN DW, Lin L, Mao YP, Chen CY, et al
    Comparison of Normal Tissue Complication Probability (NTCP) Models Using Machine Learning for Predicting Temporal Lobe Injury after Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma: a Large Registry-Based Retrospective Study from China.
    Radiother Oncol. 2021 Jan 20. pii: S0167-8140(21)00008.
    PubMed     Abstract available


  59. HUANG TT, Li SH, Chen YH, Lu HI, et al
    Definitive chemoradiotherapy for clinical T4b esophageal cancer - treatment outcomes, failure patterns, and prognostic factors.
    Radiother Oncol. 2021 Jan 19. pii: S0167-8140(21)00007.
    PubMed     Abstract available


  60. GUO Q, Zheng Y, Lin J, Xu Y, et al
    Modified Reduced-volume Intensity-modulated radiation therapy in Non-metastatic Nasopharyngeal Carcinoma: A Prospective Observation Series.
    Radiother Oncol. 2021 Jan 5. pii: S0167-8140(20)31262.
    PubMed     Abstract available


  61. HOSNI A, Chiu K, Huang SH, Xu W, et al
    Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach.
    Radiother Oncol. 2021;154:70-75.
    PubMed     Abstract available


  62. NARAYAN RK, Kumari C, Panchal P, Ghosh SK, et al
    A macroscopic salivary gland and a potential organ or simply tubarial sero-mucinous glands?
    Radiother Oncol. 2021;154:324-325.
    PubMed    


  63. YAN D, Chen S, Krauss DJ, Deraniyagala R, et al
    Inter/intra-tumoral dose response variations assessed using FDG-PET/CT feedback images: Impact on tumor control and treatment dose prescription.
    Radiother Oncol. 2021;154:235-242.
    PubMed     Abstract available


  64. VALSTAR MH, de Bakker BS, Steenbakkers RJHM, de Jong KH, et al
    The tubarial salivary glands: A potential new organ at risk for radiotherapy.
    Radiother Oncol. 2021;154:292-298.
    PubMed     Abstract available


  65. WAGENAAR D, Kierkels RGJ, van der Schaaf A, Meijers A, et al
    Head and neck IMPT probabilistic dose accumulation: Feasibility of a 2 mm setup uncertainty setting.
    Radiother Oncol. 2021;154:45-52.
    PubMed     Abstract available


  66. QIU X, Xu T, Li M, Fei Z, et al
    Response to Chai' letter: What caused the difference in prognosis among different physicians?
    Radiother Oncol. 2021;154:e20-e21.
    PubMed    


    December 2020
  67. FAN KH, Yeh CH, Hung SP, Kang CJ, et al
    Prognostic value of radiologic extranodal extension in patients with hypopharyngeal cancer treated with primary chemoradiation.
    Radiother Oncol. 2020 Dec 29. pii: S0167-8140(20)31255.
    PubMed     Abstract available


  68. XIANG M, Gensheimer MF, Pollom EL, Holsinger FC, et al
    Prolongation of definitive head and neck cancer radiotherapy: Survival impact and predisposing factors.
    Radiother Oncol. 2020 Dec 28. pii: S0167-8140(20)31251.
    PubMed     Abstract available


  69. LIANG SB, Chen LS, Chen HY, Yang XL, et al
    Prognostic influence of prevertebral space involvement in nasopharyngeal carcinoma: a retrospective study.
    Radiother Oncol. 2020 Dec 10. pii: S0167-8140(20)31231.
    PubMed     Abstract available


  70. VAN DER VEEN J, Willems S, Bollen H, Maes F, et al
    Deep learning for elective neck delineation: More consistent and time efficient.
    Radiother Oncol. 2020;153:180-188.
    PubMed     Abstract available


    November 2020
  71. RUHLE A, Stromberger C, Haehl E, Senger C, et al
    Development and validation of a novel prognostic score for elderly head-and-neck cancer patients undergoing radiotherapy or chemoradiation.
    Radiother Oncol. 2020 Nov 24. pii: S0167-8140(20)31193.
    PubMed     Abstract available


  72. LIANG SB, Chen LS, Yang XL, Chen DM, et al
    Influence of Tumor Necrosis on Treatment Sensitivity and Long-term Survival in Nasopharyngeal Carcinoma.
    Radiother Oncol. 2020 Nov 17. pii: S0167-8140(20)31165.
    PubMed     Abstract available


  73. HIROSE K, Konno A, Hiratsuka J, Yoshimoto S, et al
    Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan((10)B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial.
    Radiother Oncol. 2020 Nov 10. pii: S0167-8140(20)30890.
    PubMed     Abstract available


    October 2020
  74. CHEN NB, Li QW, Li S, Guo SP, et al
    Docetaxel and nedaplatin twice a week with concurrent definitive radiotherapy in inoperable esophageal squamous cell carcinoma: a phase I trial (GASTO-1021).
    Radiother Oncol. 2020 Oct 31. pii: S0167-8140(20)30882.
    PubMed     Abstract available


  75. ZSCHAECK S, Zophel K, Seidlitz A, Zips D, et al
    Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer.
    Radiother Oncol. 2020;155:204-211.
    PubMed     Abstract available


  76. VAN ROSSUM PSN, Jeene PM, Rozema T, Braam PM, et al
    Patient-reported outcomes after external beam radiotherapy versus brachytherapy for palliation of dysphagia in esophageal cancer: a matched comparison of two prospective trials.
    Radiother Oncol. 2020 Oct 13. pii: S0167-8140(20)30845.
    PubMed     Abstract available


  77. LUO WJ, Zou WQ, Liang SB, Chen L, et al
    Combining tumor response and personalized risk assessment: potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Radiother Oncol. 2020 Oct 8. pii: S0167-8140(20)30841.
    PubMed     Abstract available


  78. IORIO GC, Ricardi U, Franco P
    The importance of IL-6 blockade beyond the COVID-19 pandemic: Consideration for cancer care.
    Radiother Oncol. 2020;151:24-25.
    PubMed    


  79. LIU WC, Liu HE, Kao YW, Qin L, et al
    Definitive radiotherapy or surgery for early oral squamous cell carcinoma in old and very old patients: A propensity-score-matched, nationwide, population-based cohort study.
    Radiother Oncol. 2020;151:214-221.
    PubMed     Abstract available


  80. HAMILTON SN, Urban R, Liu A, Chau N, et al
    Population-based outcomes by immunosuppressed status in patients undergoing radiotherapy for oropharyngeal cancer.
    Radiother Oncol. 2020;151:110-117.
    PubMed     Abstract available


  81. LAI TY, Yeh CM, Hu YW, Liu CJ, et al
    Hospital volume and physician volume in association with survival in patients with nasopharyngeal cancer after radiation therapy.
    Radiother Oncol. 2020;151:190-199.
    PubMed     Abstract available


  82. LERCH S, Berthold S, Ziemann F, Dreffke K, et al
    HPV-positive HNSCC cell lines show strongly enhanced radiosensitivity after photon but not after carbon ion irradiation.
    Radiother Oncol. 2020;151:134-140.
    PubMed     Abstract available


  83. SHARMA MB, Jensen K, Urbak SF, Funding M, et al
    A multidimensional cohort study of late toxicity after intensity modulated radiotherapy for sinonasal cancer.
    Radiother Oncol. 2020;151:58-65.
    PubMed     Abstract available


  84. ENGESETH GM, Stieb S, Mohamed ASR, He R, et al
    Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers.
    Radiother Oncol. 2020;151:119-125.
    PubMed     Abstract available


  85. ANAKOTTA RM, van der Laan HP, Visser S, Ribeiro CO, et al
    Weekly robustness evaluation of intensity-modulated proton therapy for oesophageal cancer.
    Radiother Oncol. 2020;151:66-72.
    PubMed     Abstract available


    September 2020
  86. LI J, Wen Y, Xiang Z, Du H, et al
    Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer.
    Radiother Oncol. 2020 Sep 24. pii: S0167-8140(20)30817.
    PubMed     Abstract available


  87. LIN CH, Chou WC, Wu YY, Lin CY, et al
    Prognostic significance of dynamic changes in lymphocyte-to-monocyte ratio in patients with head and neck cancer treated with radiotherapy: results from a large cohort study.
    Radiother Oncol. 2020 Sep 14. pii: S0167-8140(20)30784.
    PubMed     Abstract available


  88. GARCIA-CONSUEGRA A, Gimeno Morales M, Cambeiro M, Tagliaferri L, et al
    Dose Volume Histogram Constraints in Patients with Head and Neck Cancer treated with Surgery and Adjuvant HDR Brachytherapy: A Proposal of the Head and Neck and Skin GEC ESTRO Working Group.
    Radiother Oncol. 2020 Sep 14. pii: S0167-8140(20)30787.
    PubMed     Abstract available


  89. HU Y, Xie C, Yang H, Wk Ho J, et al
    Computed tomography-based deep-learning prediction of neoadjuvant chemoradiotherapy treatment response in esophageal squamous cell carcinoma.
    Radiother Oncol. 2020 Sep 14. pii: S0167-8140(20)30786.
    PubMed     Abstract available


  90. LE GUEVELOU J, Bastit V, Marcy PY, Lasne-Cardon A, et al
    Flap Delineation Guidelines in Postoperative Head and Neck Radiation Therapy for head and neck cancers.
    Radiother Oncol. 2020 Sep 2. pii: S0167-8140(20)30754.
    PubMed     Abstract available


  91. DAHELE M, Tol JP, Vergeer MR, Jansen F, et al
    Is the introduction of more advanced radiotherapy techniques for locally-advanced head and neck cancer associated with improved quality of life and reduced symptom burden?
    Radiother Oncol. 2020 Sep 2. pii: S0167-8140(20)30755.
    PubMed     Abstract available


  92. SHAO CH, Chiang CC, Huang TW
    Exercise therapy for cancer therapy-induced trismus in patients with head and neck cancer: a systematic review and meta-analysis of randomized controlled trials.
    Radiother Oncol. 2020 Sep 2. pii: S0167-8140(20)30753.
    PubMed     Abstract available


    August 2020
  93. XU C, Zhang Y, Chen L, Li WF, et al
    Association between outcome disparities and pragmatic features related to clinical trial and real-world settings in nasopharyngeal carcinoma: A population-based retrospective cohort study, 2006-2016.
    Radiother Oncol. 2020 Aug 28. pii: S0167-8140(20)30737.
    PubMed     Abstract available


  94. KANAYAMA N, Otozai S, Yoshii T, Toratani M, et al
    Death unrelated to cancer and death from aspiration pneumonia after definitive radiotherapy for head and neck cancer.
    Radiother Oncol. 2020 Aug 28. pii: S0167-8140(20)30733.
    PubMed     Abstract available


  95. SAKSO M, Mortensen LS, Primdahl H, Johansen J, et al
    Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: Long-term results from the DAHANCA 24 trial (NCT01017224).
    Radiother Oncol. 2020 Aug 14. pii: S0167-8140(20)30724.
    PubMed     Abstract available


  96. DANIELS CP, Yu-Hao Liu H, Bernard A, Williams C, et al
    The declining role of post-treatment neck dissection in human papillomavirus-associated oropharyngeal cancer.
    Radiother Oncol. 2020 Aug 13. pii: S0167-8140(20)30722.
    PubMed     Abstract available


  97. JENSEN K, Friborg J, Hansen CR, Samsoe E, et al
    The danish head and neck cancer group (DAHANCA) 2020 radiotherapy guidelines.
    Radiother Oncol. 2020 Aug 8. pii: S0167-8140(20)30685.
    PubMed    


  98. TAMBAS M, J H M Steenbakkers R, van der Laan HP, Wolters AM, et al
    First experience with model-based selection of head and neck cancer patients for proton therapy.
    Radiother Oncol. 2020 Aug 5. pii: S0167-8140(20)30715.
    PubMed     Abstract available


  99. BEUKEMA JC, Kawaguchi Y, Sijtsema NM, Zhai TT, et al
    Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients?
    Radiother Oncol. 2020;149:222-227.
    PubMed     Abstract available


  100. GOTTGENS EL, Bussink J, Ansems M, Hammond EM, et al
    AKT inhibition as a strategy for targeting hypoxic HPV-positive HNSCC.
    Radiother Oncol. 2020;149:1-7.
    PubMed     Abstract available


    July 2020
  101. THOMSON DJ, Palma D, Guckenberger M, Balermpas P, et al
    Reprint of: Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement.
    Radiother Oncol. 2020 Jul 27. pii: S0167-8140(20)30200.
    PubMed     Abstract available


  102. HILKE FJ, Muyas F, Admard J, Kootz B, et al
    Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy.
    Radiother Oncol. 2020 Jul 17. pii: S0167-8140(20)30421.
    PubMed     Abstract available


  103. MA H, Liang S, Cui C, Zhang Y, et al
    Prognostic significance of quantitative metastatic lymph node burden on magnetic resonance imaging in nasopharyngeal carcinoma:a retrospective study of 1224 patients from two centers.
    Radiother Oncol. 2020 Jul 14. pii: S0167-8140(20)30416.
    PubMed     Abstract available


  104. JOURNY N, Schonfeld SJ, Hauptmann M, Roberti S, et al
    Dose-volume effects of breast cancer radiation therapy on the risk of second oesophageal cancer.
    Radiother Oncol. 2020 Jul 14. pii: S0167-8140(20)30415.
    PubMed     Abstract available


  105. HONG RIM C
    Letter to the editor regarding the article "Selection of a high-level physician may help improve outcomes of nasopharyngeal carcinoma" by Fei et al.
    Radiother Oncol. 2020 Jul 13. pii: S0167-8140(20)30413.
    PubMed    


  106. CELLINI F, Antonietta Gambacorta M, Carlo Mattiucci G, Valentini V, et al
    Role of neoadjuvant radiochemotherapy for esophageal cancers over pre/peri-operative chemotherapy in the era of COVID-19 and beyond.
    Radiother Oncol. 2020 Jul 13. pii: S0167-8140(20)30398.
    PubMed    


  107. TCHELEBI LT, Goodman K
    Response to, "Role of neoadjuvant radiochemotherapy for esophageal cancers over pre/peri-operative chemotherapy in the era of COVID-19 and beyond".
    Radiother Oncol. 2020 Jul 13. pii: S0167-8140(20)30404.
    PubMed    


  108. ZHONG LZ, Fang XL, Dong D, Peng H, et al
    A deep learning MR-based radiomic nomogram may predict survival for nasopharyngeal carcinoma patients with stage T3N1M0.
    Radiother Oncol. 2020 Jul 4. pii: S0167-8140(20)30387.
    PubMed     Abstract available


  109. PENG Y, Chen S, Qin A, Chen M, et al
    Magnetic resonance-based synthetic computed tomography images generated using generative adversarial networks for nasopharyngeal carcinoma radiotherapy treatment planning.
    Radiother Oncol. 2020 Jul 2. pii: S0167-8140(20)30385.
    PubMed     Abstract available


  110. WENTZEL A, Hanula P, van Dijk LV, Elgohari B, et al
    Precision toxicity correlates of tumor spatial proximity to organs at risk in cancer patients receiving intensity-modulated radiotherapy.
    Radiother Oncol. 2020;148:245-251.
    PubMed     Abstract available


  111. VAN DEN BOSCH L, Schuit E, van der Laan HP, Reitsma JB, et al
    Key challenges in normal tissue complication probability model development and validation: towards a comprehensive strategy.
    Radiother Oncol. 2020;148:151-156.
    PubMed     Abstract available


  112. KAANDERS JHAM, van den Bosch S, Dijkema T, Al-Mamgani A, et al
    Advances in cancer imaging require renewed radiotherapy dose and target volume concepts.
    Radiother Oncol. 2020;148:140-142.
    PubMed     Abstract available


  113. GRANT SR, Hutcheson KA, Ye R, Garden AS, et al
    Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer.
    Radiother Oncol. 2020;148:133-139.
    PubMed     Abstract available


  114. SAKSO M, Jensen K, Andersen M, Hansen CR, et al
    DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx,
    Radiother Oncol. 2020;148:65-72.
    PubMed     Abstract available


  115. WILKIE JR, Mierzwa ML, Casper KA, Mayo CS, et al
    Predicting late radiation-induced xerostomia with parotid gland PET biomarkers and dose metrics.
    Radiother Oncol. 2020;148:30-37.
    PubMed     Abstract available


    June 2020
  116. SHAHID IQBAL M, Kovarik J, Kelly C
    Challenges in conducting large randomised control trials of palliative radiotherapy in head and neck cancer.
    Radiother Oncol. 2020 Jun 27. pii: S0167-8140(20)30351.
    PubMed    


  117. RULACH R, Zhou S, Paterson C
    Letter to editor regarding Urban et al., FDG-PET/CT scan assessment of response 12 weeks post radical radiotherapy in oropharynx head and neck cancer: The impact of p16 status.
    Radiother Oncol. 2020 Jun 24. pii: S0167-8140(20)30357.
    PubMed    


  118. JIN J, Guo Y, Dong X, Liu J, et al
    Methylation-associated silencing of miR-193b improves the radiotherapy sensitivity of esophageal cancer cells by targeting cyclin D1 in areas with zinc deficiency.
    Radiother Oncol. 2020 Jun 21. pii: S0167-8140(20)30347.
    PubMed     Abstract available


  119. WIEDENMANN N, Grosu AL, Buchert M, Rischke HC, et al
    The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.
    Radiother Oncol. 2020 Jun 13. pii: S0167-8140(20)30336.
    PubMed     Abstract available


  120. LAN X, Chan JYK, Pu JJ, Qiao W, et al
    Saliva electrolyte analysis and xerostomia-related quality of life in nasopharyngeal carcinoma patients following intensity-modulated radiation therapy.
    Radiother Oncol. 2020 Jun 13. pii: S0167-8140(20)30339.
    PubMed     Abstract available


  121. RIESTERER O, Pruschy M, Bender S, Sharma A, et al
    Consolidation cetuximab after concurrent triplet radiochemotherapy + cetuximab in patients with advanced head and neck cancer: A randomized phase II study.
    Radiother Oncol. 2020 Jun 12. pii: S0167-8140(20)30334.
    PubMed     Abstract available


  122. VAN DER HEIJDEN M, Essers PBM, Verhagen CVM, Willems SM, et al
    Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy.
    Radiother Oncol. 2020;147:186-194.
    PubMed     Abstract available


  123. MANZAR GS, Lester SC, Routman DM, Harmsen WS, et al
    Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer.
    Radiother Oncol. 2020;147:64-74.
    PubMed     Abstract available


  124. HANSEN CR, Bertelsen A, Zukauskaite R, Johnsen L, et al
    Prediction of radiation-induced mucositis of H&N cancer patients based on a large patient cohort.
    Radiother Oncol. 2020;147:15-21.
    PubMed     Abstract available


    May 2020
  125. LAN K, Zhu J, Zhang J, Zhou S, et al
    Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy.
    Radiother Oncol. 2020 May 28. pii: S0167-8140(20)30292.
    PubMed     Abstract available


  126. SO TH, Lam KO
    The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy: Asian perspectives in the immunotherapy era.
    Radiother Oncol. 2020 May 19. pii: S0167-8140(20)30281.
    PubMed    


  127. TINUSZ B, Soos A, Hegyi P, Sarlos P, et al
    Efficacy and safety of stenting and additional oncological treatment versus stenting alone in unresectable esophageal cancer: a meta-analysis and systematic review.
    Radiother Oncol. 2020 May 15. pii: S0167-8140(20)30268.
    PubMed     Abstract available


  128. ZSCHAECK S, Lock S, Hofheinz F, Zips D, et al
    Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy.
    Radiother Oncol. 2020 May 14. pii: S0167-8140(20)30275.
    PubMed     Abstract available


  129. TAO Y, Auperin A, Blanchard P, Alfonsi M, et al
    Concurrent cisplatin and Dose escalation with Intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
    Radiother Oncol. 2020 May 14. pii: S0167-8140(20)30274.
    PubMed     Abstract available


  130. AL-MAMGANI A, Kessels R, Verhoef CG, Navran A, et al
    Randomized controlled trial to identify the optimal radiotherapy scheme for palliative treatment of incurable head and neck squamous cell carcinoma.
    Radiother Oncol. 2020 May 14. pii: S0167-8140(20)30273.
    PubMed     Abstract available


    April 2020
  131. ANDERSON JL, Newman NB, Anderson C, Sherry AD, et al
    Mean cardiopulmonary dose and vertebral marrow dose differentially predict lineage-specific leukopenia kinetics during radiotherapy for esophageal cancer.
    Radiother Oncol. 2020 Apr 11. pii: S0167-8140(19)33508.
    PubMed     Abstract available


  132. ZHOU S, Huang H, Chen Q, Tan KS, et al
    Long-term defects of nasal epithelium barrier functions in patients with nasopharyngeal carcinoma post chemo-radiotherapy.
    Radiother Oncol. 2020;148:116-125.
    PubMed     Abstract available


  133. VAN RIJN-DEKKER MI, van den Bosch L, van den Hoek JGM, Bijl HP, et al
    Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy.
    Radiother Oncol. 2020;147:103-110.
    PubMed     Abstract available


  134. URBAN R, Godoy T, Olson R, Wu J, et al
    FDG-PET/CT scan assessment of response 12 weeks post radical radiotherapy in oropharynx head and neck cancer: The impact of p16 status.
    Radiother Oncol. 2020;148:14-20.
    PubMed     Abstract available


  135. VISCHIONI B, Dhanireddy B, Severo C, Bonora M, et al
    Reirradiation of salivary gland tumors with carbon ion radiotherapy at CNAO.
    Radiother Oncol. 2020;145:172-177.
    PubMed     Abstract available


  136. DE FELICE F, Bird T, Michaelidou A, Thavaraj S, et al
    Radical (chemo)radiotherapy in oropharyngeal squamous cell carcinoma: Comparison of TNM 7th and 8th staging systems.
    Radiother Oncol. 2020;145:146-153.
    PubMed     Abstract available


  137. NG SP, Bahig H, Jethanandani A, Pollard C, et al
    Lymphopenia during radiotherapy in patients with oropharyngeal cancer.
    Radiother Oncol. 2020;145:95-100.
    PubMed     Abstract available


    March 2020
  138. DE VEIJ MESTDAGH PD, Walraven I, Vogel WV, Schreuder WH, et al
    SPECT/CT-guided elective nodal irradiation for head and neck cancer is oncologically safe and less toxic: A potentially practice-changing approach.
    Radiother Oncol. 2020;147:56-63.
    PubMed     Abstract available


  139. FEI Z, Qiu X, Li Y, Huang Y, et al
    Selection of a high-level physician may help improve outcomes of nasopharyngeal carcinoma.
    Radiother Oncol. 2020;147:130-135.
    PubMed     Abstract available


  140. BOEKHOFF MR, Defize IL, Borggreve AS, Takahashi N, et al
    3-Dimensional target coverage assessment for MRI guided esophageal cancer radiotherapy.
    Radiother Oncol. 2020;147:1-7.
    PubMed     Abstract available


  141. BEDDOK A, Vela A, Calugaru V, Tessonnier T, et al
    Proton therapy for head and neck squamous cell carcinomas: A review of the physical and clinical challenges.
    Radiother Oncol. 2020;147:30-39.
    PubMed     Abstract available


  142. DE FELICE F, Polimeni A, Valentini V
    The impact of Coronavirus (COVID-19) on head and neck cancer patients' care.
    Radiother Oncol. 2020;147:84-85.
    PubMed    


  143. XU C, Jin JY, Zhang M, Liu A, et al
    The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy.
    Radiother Oncol. 2020;146:180-186.
    PubMed     Abstract available


  144. SHARABIANI M, Clementel E, Andratschke N, Hurkmans C, et al
    Generalizability assessment of head and neck cancer NTCP models based on the TRIPOD criteria.
    Radiother Oncol. 2020;146:143-150.
    PubMed     Abstract available


  145. WONG J, Fong A, McVicar N, Smith S, et al
    Comparing deep learning-based auto-segmentation of organs at risk and clinical target volumes to expert inter-observer variability in radiotherapy planning.
    Radiother Oncol. 2020;144:152-158.
    PubMed     Abstract available


  146. HUANG SH, O'Sullivan B, Su J, Bartlett E, et al
    Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification.
    Radiother Oncol. 2020;144:13-22.
    PubMed     Abstract available


    February 2020
  147. ZHAI TT, Langendijk JA, van Dijk LV, van der Schaaf A, et al
    Pre-treatment radiomic features predict individual lymph node failure for head and neck cancer patients.
    Radiother Oncol. 2020;146:58-65.
    PubMed     Abstract available


  148. FIETKAU R, Hecht M, Hofner B, Lubgan D, et al
    Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial.
    Radiother Oncol. 2020;144:209-217.
    PubMed     Abstract available


  149. SARAH D, Daan N, Frederic D, Jean-Francois D, et al
    Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome.
    Radiother Oncol. 2020 Feb 7. pii: S0167-8140(20)30017.
    PubMed     Abstract available


    January 2020
  150. LI WZ, Liu GY, Lin LF, Lv SH, et al
    MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma: Prognostic value and a nomogram for the pretherapy prediction of it.
    Radiother Oncol. 2020;145:101-108.
    PubMed     Abstract available


  151. KAAE JK, Stenfeldt L, Hyrup B, Brink C, et al
    A randomized phase III trial for alleviating radiation-induced xerostomia with chewing gum.
    Radiother Oncol. 2020;142:72-78.
    PubMed     Abstract available


  152. VOLLENBROCK SE, Voncken FEM, Bartels LW, Beets-Tan RGH, et al
    Diffusion-weighted MRI with ADC mapping for response prediction and assessment of oesophageal cancer: A systematic review.
    Radiother Oncol. 2020;142:17-26.
    PubMed     Abstract available


  153. VAN DIJK LV, Van den Bosch L, Aljabar P, Peressutti D, et al
    Improving automatic delineation for head and neck organs at risk by Deep Learning Contouring.
    Radiother Oncol. 2020;142:115-123.
    PubMed     Abstract available


  154. NIYAZI M, Niemierko A, Paganetti H, Sohn M, et al
    Volumetric and actuarial analysis of brain necrosis in proton therapy using a novel mixture cure model.
    Radiother Oncol. 2020;142:154-161.
    PubMed     Abstract available


  155. IYIZOBA-EBOZUE Z, Murray LJ, Arunsingh M, Vaidyanathan S, et al
    Incidence and patterns of retropharyngeal lymph node involvement in oropharyngeal carcinoma.
    Radiother Oncol. 2020;142:92-99.
    PubMed     Abstract available


  156. BAGLEY AF, Ye R, Garden AS, Gunn GB, et al
    Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy.
    Radiother Oncol. 2020;142:133-139.
    PubMed     Abstract available


    November 2019
  157. BHATTACHARYYA T, Koto M, Ikawa H, Hayashi K, et al
    Assessment of risk factors associated with development of oronasal fistula as a late complication after carbon-ion radiotherapy for head and neck cancer.
    Radiother Oncol. 2019;144:53-58.
    PubMed     Abstract available


    October 2019
  158. LEE JY, Kim YA, Kim HS, Back JH, et al
    Radiotherapy can increase the risk of ischemic cerebrovascular disease in head and neck cancer patients: A Korean population-based cohort study.
    Radiother Oncol. 2019 Oct 17. pii: S0167-8140(19)33114.
    PubMed     Abstract available


    September 2019
  159. YANG Z, Zhang X, Wang X, Zhu XR, et al
    Multiple-CT optimization: An adaptive optimization method to account for anatomical changes in intensity-modulated proton therapy for head and neck cancers.
    Radiother Oncol. 2019 Sep 26. pii: S0167-8140(19)33094.
    PubMed     Abstract available


  160. ELBERS JBW, Al-Mamgani A, Tesseslaar MET, van den Brekel MWM, et al
    Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
    Radiother Oncol. 2019 Sep 26. pii: S0167-8140(19)33046.
    PubMed     Abstract available


  161. WANG J, Qing G, Ou X, Hu W, et al
    The impact of target dosimetry on patients' locoregional recurrence in nasopharyngeal carcinoma: A propensity score-matched analysis.
    Radiother Oncol. 2019 Sep 20. pii: S0167-8140(19)33074.
    PubMed     Abstract available


    August 2019
  162. CHAN RJ, Blades R, Jones L, Downer TR, et al
    A single-blind, randomised controlled trial of StrataXRT(R) - A silicone-based film-forming gel dressing for prophylaxis and management of radiation dermatitis in patients with head and neck cancer.
    Radiother Oncol. 2019 Aug 21. pii: S0167-8140(19)33004.
    PubMed     Abstract available


  163. KUBO N, Kubota Y, Kawamura H, Oike T, et al
    Dosimetric parameters predictive of nasolacrimal duct obstruction after carbon-ion radiotherapy for head and neck carcinoma.
    Radiother Oncol. 2019 Aug 19. pii: S0167-8140(19)33015.
    PubMed     Abstract available


  164. VAN DEN BOSCH S, Doornaert PAH, Dijkema T, Zwijnenburg EM, et al
    (18)F-FDG-PET/CT-based treatment planning for definitive (chemo)radiotherapy in patients with head and neck squamous cell carcinoma improves regional control and survival.
    Radiother Oncol. 2019 Aug 19. pii: S0167-8140(19)33018.
    PubMed     Abstract available


  165. HEUKELOM J, Kantor ME, Mohamed ASR, Elhalawani H, et al
    Differences between planned and delivered dose for head and neck cancer, and their consequences for normal tissue complication probability and treatment adaptation.
    Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)33027.
    PubMed     Abstract available


  166. ZHAN M, Zheng H, Yang Y, Xu T, et al
    Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial.
    Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)33024.
    PubMed     Abstract available


  167. RADES D, Narvaez CA, Splettstosser L, Domer C, et al
    A randomized trial (RAREST-01) comparing Mepitel(R) Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN).
    Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)33016.
    PubMed     Abstract available


    July 2019
  168. YU S, Zhang W, Ni W, Xiao Z, et al
    A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy.
    Radiother Oncol. 2019;140:159-166.
    PubMed     Abstract available


  169. RIBEIRO CO, Meijers A, Korevaar EW, Muijs CT, et al
    Comprehensive 4D robustness evaluation for pencil beam scanned proton plans.
    Radiother Oncol. 2019;136:185-189.
    PubMed     Abstract available


  170. HOFFMANN L, Poulsen PR, Ravkilde T, Bertholet J, et al
    Setup strategies and uncertainties in esophageal radiotherapy based on detailed intra- and interfractional tumor motion mapping.
    Radiother Oncol. 2019;136:161-168.
    PubMed     Abstract available


  171. ROWELL NP
    The role of external beam radiotherapy in the management of medullary carcinoma of the thyroid: A systematic review.
    Radiother Oncol. 2019;136:113-120.
    PubMed     Abstract available


    June 2019
  172. CHOW JCH, Cheung KM, Au KH, Zee BCY, et al
    Radiation-induced hypoglossal nerve palsy after definitive radiotherapy for nasopharyngeal carcinoma: Clinical predictors and dose-toxicity relationship.
    Radiother Oncol. 2019;138:93-98.
    PubMed     Abstract available


  173. HUANG L, Zhang Y, Liu Y, Li H, et al
    Prognostic value of retropharyngeal lymph node metastasis laterality in nasopharyngeal carcinoma and a proposed modification to the UICC/AJCC N staging system.
    Radiother Oncol. 2019;140:90-97.
    PubMed     Abstract available


  174. MOAN JM, Amdal CD, Malinen E, Svestad JG, et al
    The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status.
    Radiother Oncol. 2019;140:54-61.
    PubMed     Abstract available


  175. BATES JE, Morris CG, Hitchcock KE, Dziegielewski PT, et al
    Locally advanced hypopharyngeal and laryngeal cancer: Influence of HPV status.
    Radiother Oncol. 2019;140:6-9.
    PubMed     Abstract available


  176. LOCK S, Linge A, Seidlitz A, Bandurska-Luque A, et al
    Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
    Radiother Oncol. 2019;135:43-50.
    PubMed     Abstract available


    May 2019
  177. VAN DER VEEN J, Willems S, Deschuymer S, Robben D, et al
    Benefits of deep learning for delineation of organs at risk in head and neck cancer.
    Radiother Oncol. 2019;138:68-74.
    PubMed     Abstract available


  178. WILKIE JR, Mierzwa ML, Yao J, Eisbruch A, et al
    Big data analysis of associations between patient reported outcomes, observer reported toxicities, and overall quality of life in head and neck cancer patients treated with radiation therapy.
    Radiother Oncol. 2019;137:167-174.
    PubMed     Abstract available


  179. KOIVUNORO H, Kankaanranta L, Seppala T, Haapaniemi A, et al
    Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: An analysis of dose response and survival.
    Radiother Oncol. 2019;137:153-158.
    PubMed     Abstract available


  180. YAO JJ, Qi ZY, Liu ZG, Jiang GM, et al
    Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
    Radiother Oncol. 2019;137:137-144.
    PubMed     Abstract available


  181. GANJU RG, Morse R, Hoover A, TenNapel M, et al
    The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation.
    Radiother Oncol. 2019;137:117-124.
    PubMed     Abstract available


  182. LIU SL, Sun XS, Yan JJ, Chen QY, et al
    Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
    Radiother Oncol. 2019;137:83-94.
    PubMed     Abstract available


  183. BRENNER B, Purim O, Gordon N, Goshen-Lago T, et al
    The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature results from a prospective phase Ib/II trial.
    Radiother Oncol. 2019;134:74-80.
    PubMed     Abstract available


  184. LI HJ, Hu YY, Huang L, Zhou J, et al
    Subclassification of skull-base invasion for nasopharyngeal carcinoma using cluster, network and survival analyses: A double-center retrospective investigation.
    Radiother Oncol. 2019;134:37-43.
    PubMed     Abstract available


  185. GABANI P, Lin AJ, Barnes J, Oppelt P, et al
    Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma.
    Radiother Oncol. 2019;134:81-88.
    PubMed     Abstract available


  186. LUDMIR EB, Grosshans DR, McAleer MF, McGovern SL, et al
    Patterns of failure following proton beam therapy for head and neck rhabdomyosarcoma.
    Radiother Oncol. 2019;134:143-150.
    PubMed     Abstract available


  187. BRECHT S, Boda-Heggemann J, Budjan J, Siebenlist K, et al
    Radiation-induced optic neuropathy after stereotactic and image guided intensity-modulated radiation therapy (IMRT).
    Radiother Oncol. 2019;134:166-177.
    PubMed     Abstract available


  188. HOSNI A, Huang SH, Chiu K, Xu W, et al
    Validation of distant metastases risk-groups in oral cavity squamous cell carcinoma patients treated with postoperative intensity-modulated radiotherapy.
    Radiother Oncol. 2019;134:10-16.
    PubMed     Abstract available


  189. BIAU J, Lapeyre M, Troussier I, Budach W, et al
    Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update.
    Radiother Oncol. 2019;134:1-9.
    PubMed     Abstract available


    April 2019
  190. VAN DER VEEN J, Gulyban A, Nuyts S
    Interobserver variability in delineation of target volumes in head and neck cancer.
    Radiother Oncol. 2019;137:9-15.
    PubMed     Abstract available


  191. MENECEUR S, Lock S, Gudziol V, Hering S, et al
    Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens.
    Radiother Oncol. 2019;137:24-31.
    PubMed     Abstract available


  192. ZHUO X, Huang X, Yan M, Li H, et al
    Comparison between high-dose and low-dose intravenous methylprednisolone therapy in patients with brain necrosis after radiotherapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2019;137:16-23.
    PubMed     Abstract available


  193. HAYASHI K, Koto M, Ikawa H, Hagiwara Y, et al
    Feasibility of Re-irradiation using carbon ions for recurrent head and neck malignancies after carbon-ion radiotherapy.
    Radiother Oncol. 2019;136:148-153.
    PubMed     Abstract available


  194. WAGENAAR D, Kierkels RGJ, Free J, Langendijk JA, et al
    Composite minimax robust optimization of VMAT improves target coverage and reduces non-target dose in head and neck cancer patients.
    Radiother Oncol. 2019;136:71-77.
    PubMed     Abstract available


  195. DENG W, Xu C, Liu A, van Rossum PSN, et al
    The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy.
    Radiother Oncol. 2019;133:9-15.
    PubMed     Abstract available


  196. CHO WK, Oh D, Kim HK, Ahn YC, et al
    Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery.
    Radiother Oncol. 2019;133:87-92.
    PubMed     Abstract available


  197. LIAO W, Zheng Y, Bi S, Zhang B, et al
    Carotid stenosis prevalence after radiotherapy in nasopharyngeal carcinoma: A meta-analysis.
    Radiother Oncol. 2019;133:167-175.
    PubMed     Abstract available



  198. Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating.
    Radiother Oncol. 2019;133:35-42.
    PubMed     Abstract available


  199. APOLLE R, Bruckner S, Frosch S, Rehm M, et al
    Utility of fiducial markers for target positioning in proton radiotherapy of oesophageal carcinoma.
    Radiother Oncol. 2019;133:28-34.
    PubMed     Abstract available


  200. FOLEY KG, Shi Z, Whybra P, Kalendralis P, et al
    External validation of a prognostic model incorporating quantitative PET image features in oesophageal cancer.
    Radiother Oncol. 2019;133:205-212.
    PubMed     Abstract available


    March 2019
  201. KOSMIN M, Ledsam J, Romera-Paredes B, Mendes R, et al
    Rapid advances in auto-segmentation of organs at risk and target volumes in head and neck cancer.
    Radiother Oncol. 2019;135:130-140.
    PubMed     Abstract available


  202. SMITH J, Nastasi D, Tso R, Vangaveti V, et al
    The effects of continued smoking in head and neck cancer patients treated with radiotherapy: A systematic review and meta-analysis.
    Radiother Oncol. 2019;135:51-57.
    PubMed     Abstract available


  203. REID P, Marcu LG, Olver I, Moghaddasi L, et al
    Diversity of cancer stem cells in head and neck carcinomas: The role of HPV in cancer stem cell heterogeneity, plasticity and treatment response.
    Radiother Oncol. 2019;135:1-12.
    PubMed     Abstract available


  204. CAI J, Cheng J, Li H, Lin WJ, et al
    A nomogram for the prediction of cerebrovascular disease among patients with brain necrosis after radiotherapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2019;132:34-41.
    PubMed     Abstract available


  205. DE KRUIJF W, Timmers A, Dekker J, Boing-Messing F, et al
    Occurrence and mechanism of visual phosphenes in external photon beam radiation therapy and how to influence them.
    Radiother Oncol. 2019;132:109-113.
    PubMed     Abstract available


    February 2019
  206. WAN Y, Tian L, Zhang G, Xin H, et al
    The value of detailed MR imaging report of primary tumor and lymph nodes on prognostic nomograms for nasopharyngeal carcinoma after intensity-modulated radiotherapy.
    Radiother Oncol. 2019;131:35-44.
    PubMed     Abstract available


  207. CUBILLOS-MESIAS M, Troost EGC, Lohaus F, Agolli L, et al
    Including anatomical variations in robust optimization for head and neck proton therapy can reduce the need of adaptation.
    Radiother Oncol. 2019;131:127-134.
    PubMed     Abstract available


  208. VAARWERK B, Hol MLF, Schoot RA, Breunis WB, et al
    AMORE treatment as salvage treatment in children and young adults with relapsed head-neck rhabdomyosarcoma.
    Radiother Oncol. 2019;131:21-26.
    PubMed     Abstract available


  209. MOLLER DS, Alber M, Nordsmark M, Nyeng TB, et al
    Validation of a robust strategy for proton spot scanning for oesophageal cancer in the presence of anatomical changes.
    Radiother Oncol. 2019;131:174-178.
    PubMed     Abstract available


  210. MCDOWELL LJ, Ringash J, Xu W, Chan B, et al
    A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy.
    Radiother Oncol. 2019;131:179-185.
    PubMed     Abstract available


  211. ZHU JH, Wang J, Wang YG, Li M, et al
    Prospect of robotic assistance for fully automated brachytherapy seed placement into skull base: Experimental validation in phantom and cadaver.
    Radiother Oncol. 2019;131:160-165.
    PubMed     Abstract available


    January 2019
  212. TOL JP, Dahele M, Gregoire V, Overgaard J, et al
    Analysis of EORTC-1219-DAHANCA-29 trial plans demonstrates the potential of knowledge-based planning to provide patient-specific treatment plan quality assurance.
    Radiother Oncol. 2019;130:75-81.
    PubMed     Abstract available


  213. BRUIJNEN T, Stemkens B, Terhaard CHJ, Lagendijk JJW, et al
    Intrafraction motion quantification and planning target volume margin determination of head-and-neck tumors using cine magnetic resonance imaging.
    Radiother Oncol. 2019;130:82-88.
    PubMed     Abstract available


  214. DUTZ A, Lock S
    Competing risks in survival data analysis.
    Radiother Oncol. 2019;130:185-189.
    PubMed     Abstract available


  215. BANDURSKA-LUQUE A, Lock S, Haase R, Richter C, et al
    FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.
    Radiother Oncol. 2019;130:97-103.
    PubMed     Abstract available


  216. GAWRYSZUK A, Bijl HP, Holwerda M, Halmos GB, et al
    Functional Swallowing Units (FSUs) as organs-at-risk for radiotherapy. PART 2: Advanced delineation guidelines for FSUs.
    Radiother Oncol. 2019;130:68-74.
    PubMed     Abstract available


  217. HAGUE C, Beasley W, Dixon L, Gaito S, et al
    Use of a novel atlas for muscles of mastication to reduce inter observer variability in head and neck radiotherapy contouring.
    Radiother Oncol. 2019;130:56-61.
    PubMed     Abstract available


  218. WELCH ML, McIntosh C, Haibe-Kains B, Milosevic MF, et al
    Vulnerabilities of radiomic signature development: The need for safeguards.
    Radiother Oncol. 2019;130:2-9.
    PubMed     Abstract available



  219. A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findi
    Radiother Oncol. 2019;130:46-55.
    PubMed     Abstract available


    November 2018
  220. YAO JJ, Zhang F, Gao TS, Zhang WJ, et al
    Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
    Radiother Oncol. 2018 Nov 14. pii: S0167-8140(18)33542.
    PubMed     Abstract available


  221. TOPKAN E, Yildirim BA
    Epoetin receptor status may alter the outcomes in head and neck cancers treated with radiotherapy and darbepoetin-alpha.
    Radiother Oncol. 2018 Nov 7. pii: S0167-8140(18)33397.
    PubMed    


    October 2018
  222. LIANG SB, Zhang N, Chen DM, Yang XL, et al
    Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2018 Oct 23. pii: S0167-8140(18)33522.
    PubMed     Abstract available


  223. YILMAZ MT, Elmali A, Yazici G
    Comments on "High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer".
    Radiother Oncol. 2018 Oct 17. pii: S0167-8140(18)33506.
    PubMed    


  224. KANAYAMA N, Kierkels RGJ, van der Schaaf A, Steenbakkers RJHM, et al
    External validation of a multifactorial normal tissue complication probability model for tube feeding dependence at 6months after definitive radiotherapy for head and neck cancer.
    Radiother Oncol. 2018 Oct 6. pii: S0167-8140(18)33496.
    PubMed     Abstract available


    September 2018
  225. HUANG XD, Zhou GQ, Lv JW, Zhou HQ, et al
    Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis.
    Radiother Oncol. 2018 Sep 27. pii: S0167-8140(18)33487.
    PubMed     Abstract available


  226. OVERGAARD J, Alsner J
    Effect of ESA as a modifier of radiotherapy in curative intended treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Radiother Oncol. 2018 Sep 21. pii: S0167-8140(18)33452.
    PubMed    


  227. BIAU J, Dunet V, Lapeyre M, Simon C, et al
    Practical clinical guidelines for contouring the trigeminal nerve (V) and its branches in head and neck cancers.
    Radiother Oncol. 2018 Sep 8. pii: S0167-8140(18)33458.
    PubMed     Abstract available


  228. KAMAL M, Mohamed ASR, Volpe S, Zaveri J, et al
    Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry.
    Radiother Oncol. 2018;128:442-451.
    PubMed     Abstract available


  229. VAN DIJK LV, Thor M, Steenbakkers RJHM, Apte A, et al
    Parotid gland fat related Magnetic Resonance image biomarkers improve prediction of late radiation-induced xerostomia.
    Radiother Oncol. 2018;128:459-466.
    PubMed     Abstract available


  230. DIXON L, Ramasamy S, Cardale K, Dyker K, et al
    Long term patient reported swallowing function following chemoradiotherapy for oropharyngeal carcinoma.
    Radiother Oncol. 2018;128:452-458.
    PubMed     Abstract available


    August 2018
  231. OU D, Adam J, Garberis I, Blanchard P, et al
    Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy.
    Radiother Oncol. 2018 Aug 29. pii: S0167-8140(18)33451.
    PubMed     Abstract available


  232. DE VEIJ MESTDAGH PD, Janssen T, Lamers E, Carbaat C, et al
    SPECT/CT-guided elective nodal irradiation for head and neck cancer: Estimation of clinical benefits using NTCP models.
    Radiother Oncol. 2018 Aug 4. pii: S0167-8140(18)33422.
    PubMed     Abstract available


  233. LEGER S, Zwanenburg A, Pilz K, Zschaeck S, et al
    CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer.
    Radiother Oncol. 2018 Aug 4. pii: S0167-8140(18)33419.
    PubMed     Abstract available


  234. LI YJ, Luo Y, Xie XQ, Li P, et al
    The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: A prospective analysis.
    Radiother Oncol. 2018 Aug 3. pii: S0167-8140(18)33421.
    PubMed     Abstract available


    July 2018
  235. NOBLE DJ, Yeap PL, Seah SYK, Harrison K, et al
    Anatomical change during radiotherapy for head and neck cancer, and its effect on delivered dose to the spinal cord.
    Radiother Oncol. 2018 Jul 23. pii: S0167-8140(18)33396.
    PubMed     Abstract available


  236. VAN DEN BOSCH S, Dijkema T, Philippens MEP, Terhaard CHJ, et al
    Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of (18)F-FDG-PET based tumor segmentation in head and neck squamous cell carcinoma in a multicenter setting.
    Radiother Oncol. 2018 Jul 10. pii: S0167-8140(18)33352.
    PubMed     Abstract available


  237. NAVRAN A, Heemsbergen W, Janssen T, Hamming-Vrieze O, et al
    The impact of margin reduction on outcome and toxicity in head and neck cancer patients treated with image-guided volumetric modulated arc therapy (VMAT).
    Radiother Oncol. 2018 Jul 10. pii: S0167-8140(18)33347.
    PubMed     Abstract available


    May 2018
  238. TAO Y, Faivre L, Laprie A, Boisselier P, et al
    Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.
    Radiother Oncol. 2018 May 18. pii: S0167-8140(18)30246.
    PubMed     Abstract available


  239. WINTER RM, Leibfarth S, Schmidt H, Zwirner K, et al
    Assessment of image quality of a radiotherapy-specific hardware solution for PET/MRI in head and neck cancer patients.
    Radiother Oncol. 2018 May 7. pii: S0167-8140(18)30209.
    PubMed     Abstract available


  240. MICHIELS S, Poels K, Crijns W, Delombaerde L, et al
    Volumetric modulated arc therapy of head-and-neck cancer on a fast-rotating O-ring linac: Plan quality and delivery time comparison with a C-arm linac.
    Radiother Oncol. 2018 May 5. pii: S0167-8140(18)30212.
    PubMed     Abstract available


  241. VAN DEN BOSCH S, Vogel WV, Raaijmakers CP, Dijkema T, et al
    Implications of improved diagnostic imaging of small nodal metastases in head and neck cancer: Radiotherapy target volume transformation and dose de-escalation.
    Radiother Oncol. 2018 May 3. pii: S0167-8140(18)30211.
    PubMed     Abstract available


  242. CHAO M, Wei J, Narayanasamy G, Yuan Y, et al
    Three-dimensional cluster formation and structure in heterogeneous dose distribution of intensity modulated radiation therapy.
    Radiother Oncol. 2018;127:197-205.
    PubMed     Abstract available


  243. DELANEY AR, Dahele M, Slotman BJ, Verbakel WFAR, et al
    Is accurate contouring of salivary and swallowing structures necessary to spare them in head and neck VMAT plans?
    Radiother Oncol. 2018;127:190-196.
    PubMed     Abstract available


  244. MOORE SJ, Herst PM, Louwe RJW
    Review of the patient positioning reproducibility in head-and-neck radiotherapy using Statistical Process Control.
    Radiother Oncol. 2018;127:183-189.
    PubMed     Abstract available


    April 2018
  245. MURTHY V, Lewis S, Kannan S, Khadanga CR, et al
    Submandibular function recovery after IMRT in head and neck cancer: A prospective dose modelling study.
    Radiother Oncol. 2018 Apr 30. pii: S0167-8140(18)30113.
    PubMed     Abstract available


  246. GREGOIRE V, Grau C
    In reply to "A Long-Awaited Guideline for the Delineation of Primary Tumor in Head and Neck Cancer, and a Few Concerns about It" by Sezin Yuce Sari et al.
    Radiother Oncol. 2018 Apr 27. pii: S0167-8140(18)30175.
    PubMed    


  247. YUCE SARI S, Yeginer M, Cengiz M
    A long-awaited guideline for the delineation of primary tumor in head and neck cancer, and a few concerns about it.
    Radiother Oncol. 2018 Apr 24. pii: S0167-8140(18)30177.
    PubMed    


  248. ROONEY KP, Miah AB, Bhide SA, Guerrero-Urbano MT, et al
    Intensity modulated radiotherapy in locally advanced thyroid cancer: Outcomes of a sequential phase I dose-escalation study.
    Radiother Oncol. 2018;127:43-48.
    PubMed     Abstract available


  249. LINGE A, Schotz U, Lock S, Lohaus F, et al
    Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC.
    Radiother Oncol. 2018;127:27-35.
    PubMed     Abstract available


  250. CRISPIN-ORTUZAR M, Apte A, Grkovski M, Oh JH, et al
    Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [(18)F]-Fluorodeoxyglucose positron emission tomography radiomics features.
    Radiother Oncol. 2018;127:36-42.
    PubMed     Abstract available


    March 2018
  251. TAN TH, Soon YY, Cheo T, Ho F, et al
    Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
    Radiother Oncol. 2018 Mar 16. pii: S0167-8140(18)30123.
    PubMed     Abstract available


  252. SHURYAK I, Hall EJ, Brenner DJ
    Dose dependence of accelerated repopulation in head and neck cancer: Supporting evidence and clinical implications.
    Radiother Oncol. 2018 Mar 10. pii: S0167-8140(18)30098.
    PubMed     Abstract available


  253. FANG P, Jiang W, Davuluri R, Xu C, et al
    High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer.
    Radiother Oncol. 2018 Mar 9. pii: S0167-8140(18)30117.
    PubMed     Abstract available


  254. OVERGAARD J, Hoff CM, Hansen HS, Specht L, et al
    DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
    Radiother Oncol. 2018 Mar 6. pii: S0167-8140(18)30105.
    PubMed     Abstract available


  255. HE J, Cai L, Chen Y, He Y, et al
    Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway.
    Radiother Oncol. 2018 Mar 5. pii: S0167-8140(18)30063.
    PubMed     Abstract available


  256. AMPFERL R, Rodemann HP, Mayer C, Hofling TTA, et al
    Glucose starvation impairs DNA repair in tumour cells selectively by blocking histone acetylation.
    Radiother Oncol. 2018;126:465-470.
    PubMed     Abstract available


    January 2018
  257. IQBAL MS, Kelly C, Kovarik J, Goranov B, et al
    Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: A survey of UK national practice.
    Radiother Oncol. 2018 Jan 20. pii: S0167-8140(17)32734.
    PubMed    


  258. SHAHID IQBAL M, Kelly C, Kovarik J, Goranov B, et al
    Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: A systematic review.
    Radiother Oncol. 2018 Jan 19. pii: S0167-8140(17)32766.
    PubMed     Abstract available


  259. ADENIS A, Castan F, Conroy T
    Consolidation chemotherapy after definite concurrent chemoradiation in patients with non-operable esophageal cancer: Is it useful?
    Radiother Oncol. 2018 Jan 10. pii: S0167-8140(17)32773.
    PubMed    


  260. CHEN Y, Wang J
    Concurrent chemoradiotherapy alone is feasible for esophageal squamous cell carcinoma patients not suitable for surgery.
    Radiother Oncol. 2018 Jan 10. pii: S0167-8140(17)32774.
    PubMed    


  261. NEVENS D, Duprez F, Bonte K, Deron P, et al
    Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Reply to Elicin et al.
    Radiother Oncol. 2018 Jan 4. pii: S0167-8140(17)32770.
    PubMed    


  262. ZUKAUSKAITE R, Hansen CR, Grau C, Samsoe E, et al
    Local recurrences after curative IMRT for HNSCC: Effect of different GTV to high-dose CTV margins.
    Radiother Oncol. 2018;126:48-55.
    PubMed     Abstract available


  263. GREGOIRE V, Evans M, Le QT, Bourhis J, et al
    Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Onc
    Radiother Oncol. 2018;126:3-24.
    PubMed     Abstract available


  264. HANSEN CR, Johansen J, Samsoe E, Andersen E, et al
    Consequences of introducing geometric GTV to CTV margin expansion in DAHANCA contouring guidelines for head and neck radiotherapy.
    Radiother Oncol. 2018;126:43-47.
    PubMed     Abstract available


  265. LASSEN P, Lacas B, Pignon JP, Trotti A, et al
    Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project.
    Radiother Oncol. 2018;126:107-115.
    PubMed     Abstract available


  266. VAN DIJK LV, Noordzij W, Brouwer CL, Boellaard R, et al
    (18)F-FDG PET image biomarkers improve prediction of late radiation-induced xerostomia.
    Radiother Oncol. 2018;126:89-95.
    PubMed     Abstract available


    December 2017
  267. ZHANG Y, Li WF, Liu X, Chen L, et al
    Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial.
    Radiother Oncol. 2017 Dec 16. pii: S0167-8140(17)32756.
    PubMed     Abstract available


  268. SHIRAISHI Y, Fang P, Xu C, Song J, et al
    Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy.
    Radiother Oncol. 2017 Dec 13. pii: S0167-8140(17)32751.
    PubMed     Abstract available


  269. KAMAL M, Rosenthal DI, Volpe S, Goepfert RP, et al
    Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors.
    Radiother Oncol. 2017 Dec 8. pii: S0167-8140(17)32691.
    PubMed     Abstract available


    November 2017
  270. LEE AW, Ng WT, Pan JJ, Poh SS, et al
    International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma.
    Radiother Oncol. 2017 Nov 15. pii: S0167-8140(17)32686.
    PubMed     Abstract available


  271. BOGOWICZ M, Leijenaar RTH, Tanadini-Lang S, Riesterer O, et al
    Post-radiochemotherapy PET radiomics in head and neck cancer - The influence of radiomics implementation on the reproducibility of local control tumor models.
    Radiother Oncol. 2017 Nov 6. pii: S0167-8140(17)32663.
    PubMed     Abstract available


  272. TAKAHASHI N, Umezawa R, Takanami K, Yamamoto T, et al
    Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017 Nov 3. pii: S0167-8140(17)32659.
    PubMed     Abstract available


    October 2017
  273. CEREDA E, Cappello S, Colombo S, Klersy C, et al
    Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy.
    Radiother Oncol. 2017 Oct 27. pii: S0167-8140(17)32655.
    PubMed     Abstract available


  274. OU D, Garberis I, Adam J, Blanchard P, et al
    Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.
    Radiother Oncol. 2017 Oct 24. pii: S0167-8140(17)32647.
    PubMed     Abstract available


  275. DE-COLLE C, Menegakis A, Monnich D, Welz S, et al
    SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy.
    Radiother Oncol. 2017 Oct 20. pii: S0167-8140(17)32648.
    PubMed     Abstract available


  276. RAO AD, Coquia S, De Jong R, Gourin C, et al
    Effects of biodegradable hydrogel spacer injection on contralateral submandibular gland sparing in radiotherapy for head and neck cancers.
    Radiother Oncol. 2017 Oct 3. pii: S0167-8140(17)32584.
    PubMed     Abstract available


  277. COX S, Hurt C, Grenader T, Mukherjee S, et al
    The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017;125:154-159.
    PubMed     Abstract available


  278. LARUE RTHM, Van De Voorde L, van Timmeren JE, Leijenaar RTH, et al
    4DCT imaging to assess radiomics feature stability: An investigation for thoracic cancers.
    Radiother Oncol. 2017;125:147-153.
    PubMed     Abstract available


    September 2017
  279. MICHIELS S, Barragan AM, Souris K, Poels K, et al
    Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization.
    Radiother Oncol. 2017 Sep 23. pii: S0167-8140(17)32568.
    PubMed     Abstract available


  280. WOPKEN K, Bijl HP, Langendijk JA
    Prognostic factors for tube feeding dependence after curative (chemo-) radiation in head and neck cancer: A systematic review of literature.
    Radiother Oncol. 2017 Sep 21. pii: S0167-8140(17)32545.
    PubMed     Abstract available


  281. CHANG CL, Tsai HC, Lin WC, Chang JH, et al
    Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.
    Radiother Oncol. 2017 Sep 15. pii: S0167-8140(17)32548.
    PubMed     Abstract available


  282. SHIRAISHI Y, Xu C, Yang J, Komaki R, et al
    Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy.
    Radiother Oncol. 2017 Sep 13. pii: S0167-8140(17)32550.
    PubMed     Abstract available


  283. KOI L, Lock S, Linge A, Thurow C, et al
    EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models.
    Radiother Oncol. 2017;124:496-503.
    PubMed     Abstract available


  284. SCHNEIDER K, Bol V, Gregoire V
    Lack of differences in radiation-induced immunogenicity parameters between HPV-positive and HPV-negative human HNSCC cell lines.
    Radiother Oncol. 2017;124:411-417.
    PubMed     Abstract available


    August 2017
  285. YANG H, Chen X, Lin S, Rong J, et al
    Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Radiother Oncol. 2017 Aug 29. pii: S0167-8140(17)32479.
    PubMed     Abstract available


  286. LOCK S, Perrin R, Seidlitz A, Bandurska-Luque A, et al
    Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
    Radiother Oncol. 2017 Aug 23. pii: S0167-8140(17)32517.
    PubMed     Abstract available


  287. FERRIS MJ, Zhong J, Switchenko JM, Higgins KA, et al
    Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy.
    Radiother Oncol. 2017 Aug 18. pii: S0167-8140(17)32515.
    PubMed     Abstract available


  288. TONLAAR N, Galoforo S, Thibodeau BJ, Ahmed S, et al
    Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.
    Radiother Oncol. 2017 Aug 16. pii: S0167-8140(17)32501.
    PubMed     Abstract available


  289. HAWKINS PG, Lee JY, Mao Y, Li P, et al
    Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life.
    Radiother Oncol. 2017 Aug 16. pii: S0167-8140(17)32502.
    PubMed     Abstract available


  290. HUIZING FJ, Hoeben BAW, Franssen G, Lok J, et al
    Preclinical validation of 111In-girentuximab-F(ab')2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts.
    Radiother Oncol. 2017 Aug 5. pii: S0167-8140(17)32484.
    PubMed     Abstract available


  291. HOSNI A, McMullen C, Huang SH, Xu W, et al
    Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer.
    Radiother Oncol. 2017;124:225-231.
    PubMed     Abstract available



  292. Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison.
    Radiother Oncol. 2017;124:232-239.
    PubMed     Abstract available


  293. MAVROIDIS P, Price A, Fried D, Kostich M, et al
    Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
    Radiother Oncol. 2017;124:240-247.
    PubMed     Abstract available


  294. JURADO-BRUGGEMAN D, Hernandez V, Saez J, Navarro D, et al
    Multi-centre audit of VMAT planning and pre-treatment verification.
    Radiother Oncol. 2017;124:302-310.
    PubMed     Abstract available


  295. DELANEY AR, Dahele M, Tol JP, Kuijper IT, et al
    Using a knowledge-based planning solution to select patients for proton therapy.
    Radiother Oncol. 2017;124:263-270.
    PubMed     Abstract available


    July 2017
  296. MOHAMED ASR, Cardenas CE, Garden AS, Awan MJ, et al
    Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.
    Radiother Oncol. 2017 Jul 31. pii: S0167-8140(17)32476.
    PubMed     Abstract available


  297. ZHAI TT, van Dijk LV, Huang BT, Lin ZX, et al
    Improving the prediction of overall survival for head and neck cancer patients using image biomarkers in combination with clinical parameters.
    Radiother Oncol. 2017 Jul 29. pii: S0167-8140(17)32472.
    PubMed     Abstract available


  298. NEVENS D, Duprez F, Bonte K, Deron P, et al
    Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Tumor control and late toxicity.
    Radiother Oncol. 2017 Jul 26. pii: S0167-8140(17)32470.
    PubMed     Abstract available


  299. NEVENS D, Duprez F, Daisne JF, De Neve W, et al
    Dose de-escalation to the elective lymph nodes in head and neck cancer. Reply to Amdur et al.
    Radiother Oncol. 2017 Jul 24. pii: S0167-8140(17)32456.
    PubMed    


  300. RASSAMEGEVANON T, Lock S, Range U, Krause M, et al
    Tumor heterogeneity determined with a gammaH2AX foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models.
    Radiother Oncol. 2017 Jul 21. pii: S0167-8140(17)32447.
    PubMed     Abstract available


  301. XI M, Xu C, Liao Z, Hofstetter WL, et al
    The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017 Jul 4. pii: S0167-8140(17)30428.
    PubMed     Abstract available


  302. JIN P, Hulshof MCCM, van Wieringen N, Bel A, et al
    Interfractional variability of respiration-induced esophageal tumor motion quantified using fiducial markers and four-dimensional cone-beam computed tomography.
    Radiother Oncol. 2017;124:147-154.
    PubMed     Abstract available


    June 2017
  303. ZHANG D, Zhang W, Liu W, Mao Y, et al
    Human papillomavirus infection increases the chemoradiation response of esophageal squamous cell carcinoma based on P53 mutation.
    Radiother Oncol. 2017 Jun 21. pii: S0167-8140(17)30408.
    PubMed     Abstract available


  304. MCLAY M, Stedford A, Yurkowski E, Matlock S, et al
    Population-based assessment of relationship between volume of practice and outcomes in head and neck cancer patients treated in a provincially coordinated radiotherapy program.
    Radiother Oncol. 2017 Jun 15. pii: S0167-8140(17)30401.
    PubMed     Abstract available


  305. BIRD D, Patel C, Scarsbrook AF, Cosgrove V, et al
    Evaluation of clinical target volume expansion required for involved site neck radiotherapy for lymphoma to account for the absence of a pre-chemotherapy PET-CT in the radiotherapy treatment position.
    Radiother Oncol. 2017 Jun 6. pii: S0167-8140(17)30378.
    PubMed     Abstract available


  306. ZHANG W, Zhang X, Yang P, Blanchard P, et al
    Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer.
    Radiother Oncol. 2017;123:401-405.
    PubMed     Abstract available


  307. IKAWA H, Koto M, Takagi R, Ebner DK, et al
    Prognostic factors of adenoid cystic carcinoma of the head and neck in carbon-ion radiotherapy: The impact of histological subtypes.
    Radiother Oncol. 2017;123:387-393.
    PubMed     Abstract available


  308. CHEN AM, Chin R, Beron P, Yoshizaki T, et al
    Inadequate target volume delineation and local-regional recurrence after intensity-modulated radiotherapy for human papillomavirus-positive oropharynx cancer.
    Radiother Oncol. 2017;123:412-418.
    PubMed     Abstract available


    May 2017
  309. KOPPENHAGEN P, Dickreuter E, Cordes N
    Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
    Radiother Oncol. 2017 May 31. pii: S0167-8140(17)30375.
    PubMed     Abstract available


  310. CHEN J, Cai W, Zheng X, Chen Y, et al
    The pattern of cervical lymph node metastasis in thoracic esophageal squamous cell carcinoma may affect the target decision for definitive radiotherapy.
    Radiother Oncol. 2017 May 24. pii: S0167-8140(17)30152.
    PubMed     Abstract available


  311. LAI TY, Wang TH, Liu CJ, Chao TF, et al
    Risk factors for osteonecrosis of the jaw in oral cancer patients after surgery and eventual adjuvant treatment: The potential role of chemotherapy.
    Radiother Oncol. 2017 May 19. pii: S0167-8140(17)30362.
    PubMed     Abstract available


  312. FAN CY, Lin CS, Chao HL, Huang WY, et al
    Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: A Population-Based Cohort Study.
    Radiother Oncol. 2017 May 19. pii: S0167-8140(17)30367.
    PubMed     Abstract available


  313. CHRISTIAENS M, Collette S, Overgaard J, Gregoire V, et al
    Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure.
    Radiother Oncol. 2017 May 4. pii: S0167-8140(17)30160.
    PubMed     Abstract available


    April 2017
  314. LIN SH, Merrell KW, Shen J, Verma V, et al
    Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer.
    Radiother Oncol. 2017 Apr 25. pii: S0167-8140(17)30154.
    PubMed     Abstract available


  315. WELZ S, Monnich D, Pfannenberg C, Nikolaou K, et al
    Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial.
    Radiother Oncol. 2017 Apr 20. pii: S0167-8140(17)30144.
    PubMed     Abstract available


  316. RUSTHOVEN CG, Lanning RM, Jones BL, Amini A, et al
    Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy.
    Radiother Oncol. 2017 Apr 19. pii: S0167-8140(17)30130.
    PubMed     Abstract available


  317. ZHU H, Song H, Chen G, Yang X, et al
    eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma.
    Radiother Oncol. 2017 Apr 18. pii: S0167-8140(17)30140.
    PubMed     Abstract available


  318. YAMASHITA H, Abe O, Nakagawa K
    Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of 18FDG-PET scans: A long follow-up results of phase II study.
    Radiother Oncol. 2017 Apr 17. pii: S0167-8140(17)30141.
    PubMed    


  319. WU B, Kusters M, Kunze-Busch M, Dijkema T, et al
    Cross-institutional knowledge-based planning (KBP) implementation and its performance comparison to Auto-Planning Engine (APE).
    Radiother Oncol. 2017;123:57-62.
    PubMed     Abstract available


    March 2017
  320. NEVENS D, Duprez F, Daisne JF, Schatteman J, et al
    Recurrence patterns after a decreased dose of 40Gy to the elective treated neck in head and neck cancer.
    Radiother Oncol. 2017 Mar 22. pii: S0167-8140(17)30099.
    PubMed     Abstract available


  321. NAKAMURA N, Zenda S, Tahara M, Okano S, et al
    Proton beam therapy for olfactory neuroblastoma.
    Radiother Oncol. 2017;122:368-372.
    PubMed     Abstract available


    February 2017
  322. BERTHON B, Evans M, Marshall C, Palaniappan N, et al
    Head and neck target delineation using a novel PET automatic segmentation algorithm.
    Radiother Oncol. 2017;122:242-247.
    PubMed     Abstract available


  323. VAN LOON J, Even AJ, Aerts HJ, Ollers M, et al
    PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.
    Radiother Oncol. 2017;122:267-273.
    PubMed     Abstract available


  324. BUSCH CJ, Kroger MS, Jensen J, Kriegs M, et al
    G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1.
    Radiother Oncol. 2017;122:260-266.
    PubMed     Abstract available


  325. KOVACS G, Martinez-Monge R, Budrukkar A, Guinot JL, et al
    GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update - Improvement by cross sectional imaging based treatment planning and stepping source technology.
    Radiother Oncol. 2017;122:248-254.
    PubMed     Abstract available


  326. HAMMING-VRIEZE O, van Kranen SR, Heemsbergen WD, Lange CA, et al
    Analysis of GTV reduction during radiotherapy for oropharyngeal cancer: Implications for adaptive radiotherapy.
    Radiother Oncol. 2017;122:224-228.
    PubMed     Abstract available


  327. GRONLUND E, Johansson S, Montelius A, Ahnesjo A, et al
    Dose painting by numbers based on retrospectively determined recurrence probabilities.
    Radiother Oncol. 2017;122:236-241.
    PubMed     Abstract available


  328. SODERSTROM K, Nilsson P, Laurell G, Zackrisson B, et al
    Dysphagia - Results from multivariable predictive modelling on aspiration from a subset of the ARTSCAN trial.
    Radiother Oncol. 2017;122:192-199.
    PubMed     Abstract available


  329. NEVENS D, Duprez F, Daisne JF, Laenen A, et al
    Radiotherapy induced dermatitis is a strong predictor for late fibrosis in head and neck cancer. The development of a predictive model for late fibrosis.
    Radiother Oncol. 2017;122:212-216.
    PubMed     Abstract available


  330. VAN DIJK LV, Brouwer CL, van der Schaaf A, Burgerhof JG, et al
    CT image biomarkers to improve patient-specific prediction of radiation-induced xerostomia and sticky saliva.
    Radiother Oncol. 2017;122:185-191.
    PubMed     Abstract available


  331. VAN DIJK LV, Langendijk JA, Sijtsema NM, Steenbakkers RJHM, et al
    Reply letter to "Texture analysis of parotid gland as a predictive factor of radiation induced xerostomia: A subset analysis".
    Radiother Oncol. 2017;122:322.
    PubMed    


  332. NARDONE V, Tini P, Nioche C, Biondi M, et al
    Texture analysis of parotid gland as a predictive factor of radiation induced xerostomia: A subset analysis.
    Radiother Oncol. 2017;122:321.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: